Edgewise Therapeutics, Inc.
EWTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.6B
$43.07
▲ +2.67%
P/E
-23.28
Mkt Cap
$4.6B
52-Wk Range
$13.69–$48.40
52-Week Range
$13.69 - $48.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 189.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-in-class mechanism targeting root cause of dystrophinopathies rather than symptomatic treatment
- Precision medicine approach enabling targeted therapy development for genetically defined disorders
- Experienced management team with deep expertise in muscle biology and rare disease drug development
- Orphan drug designation providing regulatory incentives and market exclusivity opportunities
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Clinical development progression of EDG-5506 through Phase 2 and potential Phase 3 trials
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+23.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EWTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.53 vs -$0.47 consensus (-13.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-13.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Aug 11, 2026
vs Industry
How EWTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related